IP Library Granted Patent US 9,540,628
Granted Patent B2
US 9,540,628 · App. 14/541,792 · Granted Jan 10, 2017

Aminoacyl tRNA synthetases for modulating inflammation

Inventors: Jeffry Dean Watkins (Encinitas, CA); Alain Philippe Vasserot (Carlsbad, CA); Leslie Ann Greene (San Diego, CA); Ryan Andrew Adams (San Diego, CA); Kyle P. Chiang (Cardiff, CA); Wei Zhang (San Diego, CA); Kristi Helen Piehl (San Diego, CA); Fei Hong (San Diego, CA); Alina He (San Diego, CA)
Assignee: aTyr Pharma, Inc.
C12N9/93A61K38/53A61K39/39541A61K45/06C12Y601/01021
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,628
App. No.
14/541,792
Granted
Jan 10, 2017
Kind
B2
Abstract

Inflammatory and other cellular response-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of inflammation, such as inflammatory diseases or conditions.

Claims (7)

1. A composition comprising: a modified mRNA polynucleotide encoding a histidyl tRNA synthetase (HRS) polypeptide and a physiologically-acceptable carrier, where the HRS polypeptide is selected from (a) SEQ ID NO:28, (b) a fragment of SEQ ID NO:28 comprising at least 400 contiguous amino acids of SEQ ID NO:28, and (c) a variant which differs from SEQ ID NO: 28 by less than 10% of the residues of SEQ ID NO: 28, where the modified mRNA polynucleotide is operably linked to a heterologous translational regulatory element.

2. The composition of claim 1 , which is an aqueous solution suitable for intravenous administration to a mammalian subject in need thereof.

3. The composition of claim 1 , comprising liposomes, nanocapsules, microparticles, microspheres, lipid particles, or vesicles.

4. The composition of claim 1 , which is formulated for delivery encapsulated in a lipid particle, a liposome, a vesicle, nanosphere, or a nanoparticle.

5. The composition of claim 1 , where the heterologous translational regulatory element comprises an initiation signal.

6. The composition of claim 1 , where (b) is a fragment of SEQ ID NO:28 comprising at least 500 contiguous amino acids of SEQ ID NO:28.

7. The composition of claim 1 , where (c) is a variant which differs from SEQ ID NO:28 by less than 5% of the residues of SEQ ID NO:28.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2015
From: WATKINS, JEFFRY DEAN; VASSEROT, ALAIN PHILIPPE; GREENE, LESLIE ANN; ADAMS, RYAN ANDREW; CHIANG, KYLE P.; ZHANG, WEI; PIEHL, KRISTI HELEN; HONG, FEI; HE, ALINA
To: ATYR PHARMA, INC.
Reel/Frame 034890/0294 →
Continuity (6)
Continuation 13762151 · Feb 7, 2013
Continuation 13514952
Provisional Application 61285923 · Dec 11, 2009
Provisional Application 61285913 · Dec 11, 2009
Provisional Application 61285919 · Dec 11, 2009
Related Publication 20150140072A1 · May 21, 2015